Factores de riesgo de esteatosis hepática metabólica con alta sospecha de fibrosis avanzada en pacientes delgados atendidos en el Hospital Nacional Dos de Mayo 2012-2022

Gonzalo Miranda Manrique; Herman Vildózola Gonzales

doi:10.47892/rgp.2025.451.1847

Autores/as

Gonzalo Miranda Manrique Hospital Nacional Dos de Mayo, Lima, Perú. https://orcid.org/0000-0003-0162-1952
Herman Vildózola Gonzales Universidad Nacional Mayor de San Marcos, Lima, Perú. https://orcid.org/0000-0002-0597-9751

DOI:

https://doi.org/10.47892/rgp.2025.451.1847

Palabras clave:

Delgadez, esteatohepatitis, Fibrosis hepática

Resumen

Objetivo: Determinar los factores de riesgo sociodemográficos, antropométricos, bioquímico- metabólicos, y presencia de comorbilidades asociados a esteatosis hepática metabólica con alta sospecha de fibrosis avanzada en pacientes delgados comparados con pacientes con sobrepeso u obesidad, atendidos en el Hospital Nacional Dos de Mayo 2012- 2022. Materiales y métodos: La muestra incluyó 160 pacientes, 80 casos y 80 controles de historias clínicas de pacientes atendidos en el Consultorio de Endocrinología. La investigación fue tipo cuantitativo, observacional y analítico de casos y controles. Evaluó variables sociodemográficas, clínicas, bioquímicas y comorbilidades. Se empleó análisis descriptivo. Se aplicó pruebas de Chi cuadrado , cálculo de OR e intervalo de confianza y se realizó un análisis de regresión logística para evaluar variables confusoras. Resultados: Sociodemográficos: 77,5% de sexo femenino y 36,3% mayor de 60 años p<0,05. Antropométricos: 52,5% tenían perímetro abdominal anormal. Bioquímico: 83,8% HDL bajo p<0,05 OR 10,6; 68,8% hipercolesterolemia <0,05; 72,5% hipertrigliceridemia p<0,05 OR 1,78; 61,3% HbA1c elevado p=0,48; 86,3% LDL elevado p>0,05 y 93,8%, Ferritina aumentada p<0,05 OR 11,8. Clínico: Síndrome metabólico p<0,05 1,22 (0,9-1,44) y dentro de las comorbilidades 62,5% presentaron diabetes mellitus p=0,26. Tras el análisis de regresión logística: Ferritina, HDL disminuido e hipertrigliceridemia con valor p<0,05. Conclusiones: La ferritina aumentada, HDL disminuido e hipertrigliceridemia influyen en el riesgo de aparición de la disfunción metabólica asociada a esteatosis con alta sospecha de fibrosis avanzada en pacientes delgados atendidos en el Hospital Nacional Dos de Mayo 2012-2022.

Descargas

Métricas

Visualizaciones del PDF

35

|

Citas

Dyson J, Day C. Treatment of Non-Alcoholic Fatty Liver Disease. Dig Dis. 2014;32(5):597-604. doi: 10.1159/000360511.

Milic S, Mikolasevic I, Krznaric-Zrnic I, Stanic M, Poropat G, Stimac D, et al. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options. Drug Des Devel Ther. 2015;9:4835-45. doi: 10.2147/DDDT.S64877.

Golabi P, Paik J, Fukui N, Locklear CT, de Avilla L, Younossi ZM. Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for Mortality. Clin Diabetes. 2019;37(1):65-72. doi: 10.2337/cd18-0026.

Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577-1586. doi: 10.1002/hep.28785.

Manning PJ, Sutherland WH, Walker RJ, Williams SM, De Jong SA, Ryalls AR, et al. Effect of high-dose vitamin E on insulin resistance and associated parameters in overweight subjects. Diabetes Care. 2004;27(9):2166-71. doi: 10.2337/diacare.27.9.2166.

Zarean E, Goujani R, Rahimian G, Ahamdi A. Prevalence and risk factors of non-alcoholic fatty liver disease in southwest Iran: a population-based case-control study. Clin Exp Hepatol. 2019;5(3):224-231. doi: 10.5114/ceh.2019.87635.

Bril F, Cusi K. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Diabetes Care. 2017;40(3):419-430. doi: 10.2337/dc16-1787.

Albhaisi S, Chowdhury A, Sanyal AJ. Non-alcoholic fatty liver disease in lean individuals. JHEP Rep. 2019;1(4):329-341. doi: 10.1016/j.jhepr.2019.08.002.

Han X, Kong J, Zhang H, Zhao Y, Zheng Y, Wei C. Triglycerides Mediate the Influence of Body Mass Index on Non-Alcoholic Fatty Liver Disease in a Non-Obese Chinese Population with Normal Low-Density Lipoprotein Cholesterol Levels. Obes Facts. 2024;17(2):191-200. doi: 10.1159/000536447.

Xing J, Guan X, Zhang Q, Chen S, Wu S, Sun X. Triglycerides mediate body mass index and nonalcoholic fatty liver disease: a population-based study. Obes Facts. 2021;14(2):190-6. doi: 10.1159/000514848.

Chrysavgis L, Ztriva E, Protopapas A, Tziomalos K, Cholongitas E. Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management. World J Gastroenterol. 2020;26(42):6514-6528 doi: 10.3748/wjg.v26.i42.6514.

Kim D, Kim WR. Nonobese Fatty Liver Disease. Clin Gastroenterol Hepatol. 2017;15(4):474-485. doi: 10.1016/j. cgh.2016.08.028.

Bambha KM, Dodge JL, Gralla J, Sprague D, Biggins SW. Low, rather than high, body mass index confers increased risk for post-liver transplant death and graft loss: risk modulated by model for end-stage liver disease. Liver Transpl. 2015;21(10):1286-1294. doi: 10.1002/lt.24188.

González-Chávez A, Gómez-Miranda JE, Elizondo-Argueta S, Rangel-Mejía MP, Sánchez-Zúñiga MJ. Guía de práctica clínica de síndrome metabólico. Rev ALAD. 2019;9(5):413.

Basaranoglu M. Lean and nonobese MASLD/NASH from a hepatologist’s point of view. J Clin Gastroenterol. 2021;55(1):93- 94. doi: 10.1097/MCG.0000000000001428.

Chrysavgis L, Ztriva E, Protopapas A, Tziomalos K, Cholongitas E. Nonalcoholic fatty liver disease in lean subjects: prognosis, outcomes and management. World J Gastroenterol. 2020;26(42):6514-6528. doi: 10.3748/wjg.v26.i42.6514.

Denkmayr L, Feldman A, Stechemesser L, Eder SK, Zandanell S, Schranz M, et al. Lean patients with non-alcoholic fatty liver disease have a severe histological phenotype similar to obese patients. J Clin Med. 2018;7(12):562. doi: 10.3390/jcm7120562.

Phipps M, Wattacheril J. Non-alcoholic fatty liver disease (MASLD) in non-obese individuals. Frontline Gastroenterol. 2019;11(6):478-483. doi: 10.1136/flgastro-2018-101119.

Satapathy SK, Jiang Y, Agbim U, Wu C, Bernstein DE, Teperman LW, et al. Posttransplant outcome of lean compared with obese nonalcoholic steatohepatitis in the United States: the obesity paradox. Liver Transpl. 2020;26(1):68-79. doi: 10.1002/ lt.25672.

Wattacheril J, Sanyal AJ. Lean MASLD: an underrecognized outlier. Curr Hepatol Rep. 2016;15(2):134-139. doi: 10.1007/ s11901-016-0302-1.

Younes R, Bugianesi E. NASH in lean individuals. Semin Liver Dis. 2019;39(1):86-95. doi: 10.1055/s-0038-1677517.

Ahadi M, Molooghi K, Masoudifar N, Namdar AB, Vossoughinia H, Farzanehfar M. A review of non-alcoholic fatty liver disease in non-obese and lean individuals. J Gastroenterol Hepatol. 2021;36(6):1497-1507. doi:10.1111/jgh.15353.

Kim JW, Kim DH, Roh YK, Ju SY, Nam HY, Nam GE, et al. Serum Ferritin Levels Are Positively Associated With Metabolically Obese Normal Weight: A Nationwide Population-Based Study. Medicine (Baltimore). 2015;94(52):e2335. doi: 10.1097/ MD.0000000000002335.

Jiang Y, Zeng J, Chen B. Hemoglobin combined with triglyceride and ferritin in predicting non-alcoholic fatty liver. J Gastroenterol Hepatol. 2014;29(7):1508-14. doi: 10.1111/jgh.12580.

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966- 1986. doi: 10.1097/HEP.0000000000000520.39.

Del Campo JA, Gallego-Durán R, Gallego P, Grande L. Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD). Int J Mol Sci. 2018;19(3):911. doi: 10.3390/ ijms19030911.

Jin YJ, Kim KM, Hwang S, Lee SG, Ha TY, Song GW, et al. Exercise and diet modification in non-obese non-alcoholic fatty liver disease: analysis of biopsies of living liver donors. J Gastroenterol Hepatol. 2012;27(8):1341-7. doi: 10.1111/j.1440- 1746.2012.07165.x.

Kawanaka M, Nishino K, Kawada M, Ishii K, Tanikawa T, Katsumata R, et al. Lean nonalcoholic fatty liver disease: Agedependent differences in pathology, prognosis, and liver-related events. Hepatol Res. 2023;53(9):829-843. doi: 10.1111/ hepr.13911.

Sheu WH, Chen YT, Lee WJ, Wang CW, Lin LY. A relationship between serum ferritin and the insulin resistance syndrome is present in non-diabetic women but not in non-diabetic men. Clin Endocrinol (Oxf). 2003;58(3):380-5. doi: 10.1046/j.1365- 2265.2003.01729.x.

Wei JL, Leung JC, Loong TC, Wong GL, Yeung DK, Chan RS, et al. Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy. Am J Gastroenterol. 2015;110(9):1306-14; quiz 1315. doi: 10.1038/ajg.2015.235.

Méndez-Sánchez N, Brouwer WP, Lammert F, Yilmaz Y. Metabolic dysfunction associated fatty liver disease in healthy weight individuals. Hepatol Int. 2024;18(Suppl 2):884-896. doi: 10.1007/s12072-024-10662-w.

Njei B, Ameyaw P, Al-Ajlouni Y, Njei LP, Boateng S. Diagnosis and Management of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review. Cureus. 2024;16(10):e71451. doi:10.7759/cureus.71451.